Issue 154 • May 2025

The GLP-1 shortage is over. What’s next for compounders?

Compounding pharmacies and telehealth providers navigate the evolving GLP-1 drug supply chain.

Briefing

Thermo Fisher counters tariffs with $2bn investment 

Feature

Can AI replace medical writers? Experts say not immediately

The Big Interview

Saving ultra-rare therapies through unorthodox funding

Feature

Big pharma faces headwinds in China as vaccine sales decline

In association with

04/29/2025 12:21:00
  • Home | The GLP-1 drug shortage is over. What’s next for the compounders?
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • MilliporeSigma
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Molnar-Institute Company Insight
  • Molnar-Institute
  • ZETA
  • In Depth
  • The GLP-1 drug shortage is over. What’s next for the compounders?
  • Big pharma faces headwinds in China as vaccine sales decline
  • How can pharma manage rising trial costs?
  • Can AI replace medical writers? Experts say not immediately
  • Saving shelved ultra-rare therapies through unorthodox funding
  • Do in vivo CAR-T cell therapies have the potential to overtake ex vivo CAR-Ts?
  • Weight loss implants to increase compliance and cut admin burden for patients
  • Greens Company Insight
  • Listings
  • Events
  • Excellence Awards
  • Buyer's Guides
  • Next issue
04/29/2025 00:00:00